• Approval of E Keppra^® IV Drip Infusion use will enable uninterrupted treatment of patients temporarily unable to swallow oral E Keppra^® formulations. This product has been approved in over 40 countries and regions including in the EU and US in 2006.
• About 1% of people worldwide have epilepsy, and onset of new cases is particularly high in infants and the elderly. About 70% of patients can live seizure-free lives if they are able to continuously take anti-epileptic drugs.
• E Keppra^® (brand name outside Japan is Keppra^®) was first approved in the US in 1999 and has received approval in more than 100 countries and regions. It is a novel anti-epileptic drug prescribed to patients ranging from children to the elderly. It has been used by more than 100,000 patients in Japan.

Otsuka Pharmaceutical Co., Ltd. (headquarters: Tokyo; President and Representative Director: Taro Iwamoto;) and UCB Japan Co., Ltd. (headquarters: Tokyo; President and Representative Director: Joel Peterson) received marketing authorization in Japan on July 4, 2014, 2014 for E Keppra^® for IV Drip Infusion 500 mg (levetiracetam). E Keppra^® IV Drip Infusion is an alternative for patients who are temporarily unable to take oral formulations of E Keppra^®.